Comprehensive Guide to Nilutamide: Uses, Dosage, Side Effects, and More
What is Nilutamide?
Overview of Nilutamide
Generic Name: Nilutamide
Brand Name: Nilandron, generics
Drug Group: Nonsteroidal antiandrogen
Commonly Used For
- Treat metastatic prostate cancer.
- Manage hormone-sensitive prostate cancer.
- Support androgen deprivation therapy.
Key Characteristics
Form: Oral tablets (50 mg, 150 mg) (detailed in Dosage section).
Mechanism: Competitively inhibits androgen binding to receptors, reducing prostate cancer growth.
Approval: FDA-approved (1996 for Nilandron) and EMA-approved for prostate cancer.
Indications and Uses of Nilutamide
Nilutamide is indicated for prostate cancer management, leveraging its antiandrogenic properties to suppress tumor growth:
Metastatic Prostate Cancer: Treats stage D2 metastatic prostate cancer, often combined with surgical castration or LHRH agonists (e.g., leuprolide), improving survival rates, per urologic oncology guidelines.
Hormone-Sensitive Prostate Cancer: Manages locally advanced or metastatic hormone-sensitive prostate cancer, delaying disease progression, supported by clinical trials.
Adjuvant Therapy: Used as adjuvant therapy post-radical prostatectomy in high-risk patients, reducing recurrence, with evidence from surgical oncology studies.
Castration-Resistant Prostate Cancer (CRPC): Investigated off-label in early CRPC to delay further progression, enhancing quality of life, supported by endocrinology research.
Benign Prostatic Hyperplasia (BPH): Explored off-label to alleviate lower urinary tract symptoms in BPH, reducing prostate volume, with urology data.
Hirsutism: Employed off-label in women with hirsutism due to androgen excess (e.g., PCOS), improving cosmetic outcomes, supported by dermatology and gynecologic studies.
Acne Vulgaris: Used off-label to treat severe acne linked to androgen sensitivity, reducing sebum production, with evidence from dermatologic research.
Kennedy’s Disease (SBMA): Investigated off-label to manage symptoms of spinal and bulbar muscular atrophy, improving motor function, supported by neurology trials.
Male Pattern Baldness: Explored off-label to reduce androgen-driven hair loss, with preliminary data from trichology studies.
Endometriosis: Studied off-label in women to inhibit androgen effects on endometriotic tissue, reducing pain, with emerging gynecologic evidence.
Dosage of Nilutamide
Dosage for Adults
Metastatic Prostate Cancer:
- Initial: 300 mg once daily for 30 days, taken with or without food.
- Maintenance: 150 mg once daily, continued with castration therapy.
Adjuvant Therapy (Off-Label): 150–300 mg once daily, titrated based on PSA levels and tolerance.
Dosage for Children
Not Recommended: Nilutamide is not indicated for pediatric use due to lack of safety data.
Dosage for Pregnant Women
Pregnancy Category C: Contraindicated in women of childbearing potential; avoid unless critically necessary. Consult an obstetrician if exposure occurs.
Dosage Adjustments
Renal Impairment: No adjustment needed; monitor in severe cases (CrCl <30 mL/min).
Hepatic Impairment: Mild (Child-Pugh A): No adjustment; moderate (Child-Pugh B): Use caution; severe (Child-Pugh C): Avoid.
Elderly: Start with 150 mg once daily; increase to 300 mg if tolerated.
Concomitant Medications: Adjust if combined with CYP2C19 inhibitors/inducers (e.g., omeprazole, rifampin), altering levels.
Additional Considerations
- Take this active ingredient with or without food, using a full glass of water.
- Monitor PSA levels and liver function during therapy.
How to Use Nilutamide
Administration:
- Swallow tablets whole with water, with or without food; avoid crushing or splitting.
- Take at the same time daily for consistency, often with other ADT agents.
Timing: Use once daily, preferably in the morning or evening, as directed.
Monitoring: Watch for vision changes, yellowing skin, or signs of lung issues (e.g., shortness of breath).
Additional Tips:
- Store at 20–25°C (68–77°F), protecting from moisture and heat.
- Keep out of reach of children due to toxicity risk.
- Report severe fatigue, chest pain, or signs of allergic reaction immediately.
Contraindications for Nilutamide
Hypersensitivity: Patients with a known allergy to Nilutamide or antiandrogens.
Severe Hepatic Impairment: Contraindicated in Child-Pugh Class C due to hepatotoxicity risk.
Severe Respiratory Disease: Avoid in patients with active interstitial lung disease.
Side Effects of Nilutamide
Common Side Effects
- Hot Flashes (50–60%, manageable with hydration)
- Nausea (20–30%, relieved with food)
- Vision Changes (15–25%, transient)
- Fatigue (10–20%, decreases with rest)
- Gynecomastia (5–15%, monitored over time)
These effects may subside with dose adjustment.
Serious Side Effects
Seek immediate medical attention for:
- Hepatic: Jaundice, hepatitis, or liver failure.
- Pulmonary: Interstitial pneumonitis or fibrosis.
- Neurological: Seizures or severe dizziness.
- Cardiovascular: Hypertension or chest pain.
- Allergic: Rash, angioedema, or anaphylaxis.
Additional Notes
- Regular monitoring for liver function, lung health, and PSA levels is advised.
- Report any unusual symptoms (e.g., yellow skin, persistent cough) immediately to a healthcare provider.
Warnings & Precautions for Nilutamide
General Warnings
Hepatotoxicity: Risk of liver injury or failure; monitor liver enzymes monthly.
Interstitial Lung Disease: Risk of pneumonitis or fibrosis; assess respiratory symptoms.
Vision Disorders: Delayed adaptation to dark, chromatopsia; advise caution driving at night.
Alcohol Intolerance: Flushing and discomfort; avoid alcohol consumption.
Cardiovascular Risk: Rare increase in blood pressure; monitor closely.
Additional Warnings
Neurological Effects: Rare seizures or dizziness; report if persistent.
Metabolic Changes: May alter glucose or lipid levels; check periodically.
Bone Health: Risk of osteoporosis with long-term use; assess bone density.
Psychiatric Effects: Rare depression or anxiety; monitor mental health.
Hypersensitivity Reactions: Rare anaphylaxis; discontinue if swelling occurs.
Use in Specific Populations
- Pregnancy: Category C; contraindicated in women; use contraception in partners.
- Breastfeeding: Avoid due to potential toxicity; monitor infant if exposure occurs.
- Elderly: Higher risk of side effects; start with lower doses.
- Children: Not indicated; avoid use.
- Renal/Hepatic Impairment: Adjust dose; avoid in severe cases.
Additional Precautions
- Inform your doctor about liver disease, lung conditions, or medication history before starting this medication.
- Avoid abrupt cessation; taper if discontinuing long-term use.
Overdose and Management of Nilutamide
Overdose Symptoms
- Nausea, vomiting, or dizziness.
- Severe cases: Liver failure, lung injury, or seizures.
- Headache, vision changes, or fatigue as early signs.
- Coma with extremely high doses.
Immediate Actions
Contact the Medical Team: Seek immediate medical help.
Supportive Care: Administer IV fluids, monitor vital signs, and provide oxygen if needed.
Specific Treatment: No antidote; manage symptoms and monitor organ function.
Monitor: Check liver enzymes, lung function, and mental status for 24–72 hours.
Additional Notes
- Overdose risk is moderate; store securely.
- Report persistent symptoms (e.g., jaundice, severe breathing difficulty) promptly.
Drug Interactions with Nilutamide
This active ingredient may interact with:
- CYP2C19 Inhibitors: Increases levels (e.g., omeprazole); monitor.
- CYP2C19 Inducers: Decreases levels (e.g., rifampin); adjust dose.
- Anticoagulants: Alters bleeding risk (e.g., warfarin); monitor INR.
- Alcohol: Enhances intolerance; avoid.
- Phenytoin: Reduces efficacy; monitor seizure control.
Action: Provide your healthcare provider with a complete list of medications.
Patient Education or Lifestyle
Medication Adherence: Take this antiandrogen as prescribed to manage prostate cancer, following the exact schedule.
Monitoring: Report vision changes, jaundice, or breathing difficulty immediately.
Lifestyle: Avoid alcohol; wear sunglasses if vision is affected.
Diet: Take with or without food; maintain a balanced diet.
Emergency Awareness: Know signs of liver failure or lung issues; seek care if present.
Follow-Up: Schedule regular check-ups every 1–3 months to monitor liver, lung, and PSA levels.
Pharmacokinetics of Nilutamide
Absorption: Well-absorbed orally (peak at 1–2 hours); unaffected by food.
Distribution: Volume of distribution ~21–39 L; 80–90% protein-bound.
Metabolism: Hepatic via CYP2C19 to active metabolites.
Excretion: Primarily renal (60%) as metabolites; half-life 38–59 hours.
Half-Life: 38–59 hours, with sustained antiandrogenic effect.
Pharmacodynamics of Nilutamide
This drug exerts its effects by:
- Competitively binding to androgen receptors, blocking testosterone and dihydrotestosterone action.
- Reducing prostate cancer cell proliferation and PSA levels.
- Inducing apoptosis in androgen-dependent cells.
- Exhibiting dose-dependent risks of hepatotoxicity and lung toxicity.
Storage of Nilutamide
Temperature: Store at 20–25°C (68–77°F); protect from moisture.
Protection: Keep in original container, away from light.
Safety: Store in a locked container out of reach of children due to toxicity risk.
Disposal: Dispose of unused tablets per local regulations or consult a pharmacist.
Frequently Asked Questions (FAQs)
Q: What does Nilutamide treat?
A: This medication treats metastatic prostate cancer.
Q: Can this active ingredient cause vision changes?
A: Yes, vision changes may occur; avoid driving at night.
Q: Is Nilutamide safe for children?
A: No, it is not recommended for children.
Q: How is this drug taken?
A: Orally as tablets once daily, as directed.
Q: How long is Nilutamide treatment?
A: Long-term for prostate cancer with monitoring.
Q: Can I use Nilutamide if pregnant?
A: No, it is contraindicated; consult a doctor.
Regulatory Information
This medication is approved by:
U.S. Food and Drug Administration (FDA): Approved in 1996 (Nilandron) for metastatic prostate cancer.
European Medicines Agency (EMA): Approved for prostate cancer management.
Other Agencies: Approved globally for prostate cancer; consult local guidelines.
References
- U.S. Food and Drug Administration (FDA). (2023). Nilandron (Nilutamide) Prescribing Information.
- Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
- European Medicines Agency (EMA). (2023). Nilutamide Summary of Product Characteristics.
- EMA’s comprehensive information on the medication’s indications and precautions in Europe.
- National Institutes of Health (NIH). (2023). Nilutamide: MedlinePlus Drug Information.
- NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
- World Health Organization (WHO). (2023). WHO Model List of Essential Medicines: Nilutamide.
- WHO’s consideration of Nilutamide for cancer therapy.
- European Urology. (2022). Nilutamide in Prostate Cancer Management.
- Peer-reviewed article on Nilutamide efficacy (note: access may require a subscription).
